查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541318

2024-2032 年按产品、手术类型、最终用户和地区分類的脊椎生物製剂市场报告

Spine Biologics Market Report by Product, Surgery Type, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球脊椎生物製品市场规模达21亿美元。该市场的推动因素包括微创手术 (MIS) 的广泛采用、老年人口的不断增长、收入水平上涨导致医疗服务的机会不断增加以及脊椎疾病发病率的增加。

脊椎生物製品市场分析：

主要市场驱动因素：脊椎生物製剂市场研究表明，该市场主要是由椎间盘疾病和椎管狭窄等脊椎疾病日益流行所驱动，这些疾病通常与老化和生活方式因素有关。

主要市场趋势：在脊椎手术中使用生物製剂以促进更快的恢復和更好的结果，与医疗技术的进步保持一致，是一个明显的趋势。在脊椎生物製剂市场预测中，业界将见证人工智慧和机器学习技术相结合的持续创新，以提高脊椎生物製剂的精确度和有效性。

地理趋势：由于其先进的医疗基础设施、高额医疗支出和对脊椎疾病的认识，北美目前引领全球市场。此外，根据脊椎生物製品市场统计数据，由于医疗保健机会的增加、经济标准的提高以及老年人口的增加，亚太地区正在经历快速增长。

竞争格局：脊椎生物製剂产业的一些主要市场参与者包括 Arthrex Inc.、Alphatec Holdings Inc.、Exactech Inc.、Johnson & Johnson、Medtronic plc、NuVasive Inc.、Orthofix Medical Inc.、Stryker Corporation、Wright Medical Group NV 、Zimmer Biomet 等。

挑战与机会：市场面临的挑战包括对生物製品高成本的担忧以及可能延迟产品上市的严格监管环境。正如脊椎生物製剂市场概述中所述，与保险提供者和医疗保健机构不断加强的合作有可能改善生物治疗的取得和采用，从而产生大量机会。

脊椎生物製剂市场趋势：

脊椎疾病的盛行率不断增加

脊椎疾病的日益增多正在影响脊椎生物製剂市场的成长。此外，预期寿命的延长和生活方式问题正在刺激椎间盘疾病和椎管狭窄等退化性疾病的发展。根据世界卫生组织(WHO) 的数据，2020 年，大约每13 个人中就有1 人（即6.19 亿人）经历过腰痛(LBP)，比1990 年增加了60%。约843 例到 2050 年，这一数字将达到 100 万，这强调了脊椎问题的广泛性。发病率随80岁年龄组增加而增加，其中50-55岁年龄组发生率增加。这种广泛的盛行率需要持续开发和部署有效的治疗方法，包括生物製剂，这有助于促进骨骼生长和癒合，这使得它们对于治疗这些普遍性疾病至关重要。

微创手术 (MIS) 的采用率不断上升

脊椎疾病的微创手术 (MIS) 是首选，因为与传统的开放性手术相比，其痛苦较小且恢復时间较快。根据 IMARC GROUP 的数据，2024 年至 2032 年期间，全球微创手术市场预计将以约 6% 的年复合成长率(CAGR) 扩张。 2023 年达到 529 亿美元，预计到 2032 年市场将达到 910 亿美元。 这种增长宣告了手术方法的转变，减少了住院时间和恢復时间，这对脊椎生物製品的市场价值特别有利。

老年人口不断增加

不断增长的老年人口正在推动脊椎生物製剂市场需求。随着年龄的增长，脊椎疾病的风险增加，需要更频繁和更深入的护理。根据联合国的资料，65 岁及以上人口预计将从 2022 年的 10% 上升至 2050 年的 16%。儿童的数量。这意味着与年龄相关的脊椎疾病数量不断增加，对有效且微创治疗的需求不断增加。例如，有助于自然癒合过程的生物製剂特别适合满足这些需求，符合全球人口老化日益增长的医疗保健需求。

脊椎生物製品市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据产品、手术类型和最终用户对市场进行了分类。

按产品划分：

同种异体脊椎移植物

机械加工骨同种异体移植物

去矿骨基质

骨移植替代品

骨形态发生蛋白

合成骨移植物

基于细胞的矩阵

骨移植替代品占大部分市场份额

该报告根据产品提供了详细的市场细分和分析。这包括脊椎同种异体移植物（机械加工的同种异体骨移植、脱矿骨基质）、骨移植替代品（骨形态发生蛋白、合成骨移植物）和以细胞为基础的基质。根据该报告，骨移植替代品占最大部分。

骨移植替代品提供了传统骨移植的替代方案，规定了脊椎手术中的结构支撑并促进骨癒合过程。这些替代品包括合成材料、同种异体移植物和脱矿骨基质，并因其能够支持骨融合并抑制从患者自身采集骨骼的需要而受到提倡，从而最大限度地减少手术并发症和恢復时间。根据IMARC GROUP统计，2023年全球骨移植和替代品市场规模达32亿美元，预计到2032年将达到51亿美元，2024-2032年年复合成长率（CAGR）为5.2%。此外，生物材料、再生医学和骨移植替代品的各种进步正在见证脊椎手术中越来越多的采用，从而积极增加脊椎生物製品的市场价值。

按手术类型划分：

开放式脊椎手术

微创脊椎手术

微创脊椎手术占据业界最大份额

报告还根据手术类型对市场进行了详细的细分和分析。这包括开放性脊椎手术和微创脊椎手术。报告称，微创脊椎手术占据最大的市场份额。

微创脊椎手术主要归因于患者和医疗保健提供者对微创手术的日益偏好。微创脊椎手术与传统开放性手术相比具有多种优势，包括切口较小、失血量较少、住院时间较短、恢復时间较快。因此，它在治疗各种脊椎疾病方面广受欢迎，例如退化性椎间盘疾病、椎间盘突出、椎管狭窄和椎骨骨折。根据国家医学图书馆的数据，微创脊椎 (MIS) 手术在影像导航系统、机器人和内视镜检查方面取得了显着进展。美国每年完成超过 40 万例病例，脊椎融合术是脊椎创伤、肿瘤、结构畸形和退化性疾病的常用和既定的治疗选择。

按最终用户划分：

医院

门诊护理中心

脊椎手术中心

骨科诊所

其他的

医院代表领先的细分市场

该报告提供了基于最终用户的详细市场细分和分析。这包括医院、门诊护理中心、脊椎手术中心、骨科诊所等。报告称，医院占最大部分。

医院是专业医疗护理的主要中心，吸引了大量寻求治疗多种形式脊椎疾病（包括需要手术的脊椎疾病）的患者。此外，一些医院设有专门的脊椎中心或提供服务的科室，使其成为综合来源护理的首选中心。除此之外，医院与脊椎生物製品製造商和供应商有着强有力的合作，从而提高了设备的效率。 2022 年 6 月，Xenco Medical 透过获得美国食品药物管理局 (FDA) 的许可并推出一次性使用的 Multilevel CerviKit，扩大了其用于门诊手术中心的设备范围。它包括一整套植入物和一次性器械，用于颈椎前路的二、三和四级手术。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的脊椎生物製品市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是脊椎生物製品最大的区域市场。

北美在市场上的主导地位可归因于高度发展的医疗基础设施、创新医疗技术的高采用率以及大量脊椎疾病患者。例如，根据国家脊髓损伤协会的资料，美国约有 45 万人患有脊髓损伤 (SCI)。据估计，美国每年会出现 17,000 例新的 SCI 病例，主要源自于脊椎创伤。因此，SCI 族群发病率的增加显着增加了该地区对脊椎生物製剂治疗疾病的需求。此外，有利的报销政策、强大的研发力度以及对微创外科手术优势的认识正在为北美脊椎生物製剂市场带来收入。

竞争格局：

脊椎生物製品市场研究报告也对市场竞争格局进行了全面分析。也提供了所有主要公司的详细资料。脊椎生物製品产业的一些主要市场参与者包括 Arthrex Inc.、Alphatec Holdings Inc.、Exactech Inc.、Johnson & Johnson、Medtronic plc、NuVasive Inc.、Orthofix Medical Inc.、Stryker Corporation、Wright Medical Group NV 和齐默比美特。

（请注意，这只是关键参与者的部分列表，报告中提供了完整列表。）

目前，市场上的主要参与者正在投资研究和创新，以开发优于竞争对手的模型并提供客户寻求的解决方案。他们还努力透过发展策略联盟、收购和扩展到新市场来渗透更多市场并满足所有客户需求，以确保其产品留在市场上并满足客户的需求。例如，2023 年 10 月，全球着名的脊椎和骨科公司 Orthofix Medical Inc. 在获得 510k 许可后推出了 OsteoCove 的完整商业版本，这是一种创新的生物活性合成移植物。它以腻子和条状形式提供，经过精心开发，可为各种脊柱和骨科手术提供卓越的成骨能力和最佳的操作性能。此外，出色的行销和品牌管理也使其产品需求旺盛，这为脊椎生物製剂市场提供了积极的前景。

脊椎生物製剂市场新闻：

2022 年 8 月：Graftys SA 宣布续约与 Arthrex 的长期合同，涉及先进合成骨移植材料的多年供应协议。

2023 年 10 月：着名医疗技术公司 Stryker 推出了具有脊椎导引软体的 Q 导引系统，该系统已部署用于为 2,400 多个脊椎病例提供改进的手术规划和导航。

本报告回答的关键问题

  • 全球脊椎生物製剂市场有多大
  • 2024-2032年全球脊椎生物製剂市场的预期成长率是多少
  • 推动全球脊椎生物製品市场的关键因素是什么
  • COVID-19 对全球脊椎生物製剂市场有何影响
  • 基于产品的全球脊椎生物製品市场的细分如何
  • 根据手术类型，全球脊椎生物製品市场的细分如何
  • 基于最终用户的全球脊椎生物製品市场的细分是什么
  • 全球脊椎生物製剂市场的关键区域有哪些
  • 谁是全球脊椎生物製品市场的主要参与者/公司

本报告回答的关键问题

  • 全球脊椎生物製剂市场有多大？ 2024-2032年全球脊椎生物製品市场的预期成长率是多少？
  • 推动全球脊椎生物製品市场的关键因素是什么？
  • COVID-19 对全球脊椎生物製剂市场有何影响？
  • 基于该产品的全球脊椎生物製品市场的细分情况如何？
  • 根据手术类型，全球脊椎生物製品市场的细分情况如何？
  • 基于最终用户的全球脊椎生物製品市场的细分情况如何？
  • 全球脊椎生物製剂市场的关键区域有哪些？
  • 全球脊椎生物製品市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球脊椎生物製剂市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 同种异体脊椎移植物
    • 市场趋势
    • 关键环节
      • 机械加工骨同种异体移植物
      • 去矿骨基质
    • 市场预测
  • 骨移植替代品
    • 市场趋势
    • 关键环节
      • 骨形态发生蛋白
      • 合成骨移植物
    • 市场预测
  • 基于细胞的矩阵
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依手术类型

  • 开放式脊椎手术
    • 市场趋势
    • 市场预测
  • 微创脊椎手术
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 门诊护理中心
    • 市场趋势
    • 市场预测
  • 脊椎手术中心
    • 市场趋势
    • 市场预测
  • 骨科诊所
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Arthrex Inc
    • Alphatec Holdings Inc.
    • Exactech Inc
    • Johnson & Johnson
    • Medtronic plc
    • NuVasive Inc
    • Orthofix Medical Inc.
    • Stryker Corporation
    • Wright Medical Group NV
    • Zimmer Biomet
Product Code: SR112024A4333

The global spine biologics market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2024-2032. The market is driven by the widespread adoption of minimally invasive surgeries (MIS), the growing geriatric population, the growing access to healthcare services on account of inflating income levels, and the increasing incidence of spinal disorders.

Spine Biologics Market Analysis:

Major Market Drivers: The spine biologics market research indicates that the market is primarily driven by the increasing prevalence of spinal disorders such as disc disease and spinal stenosis, often related to aging and lifestyle factors.

Key Market Trends: There is a noticeable trend toward the use of biologics in spine surgeries to promote quicker recovery and better outcomes, aligning with advancements in medical technologies. In the spine biologics market forecast, the industry will witness ongoing innovation with the integration of artificial intelligence and machine learning technologies to enhance the precision and effectiveness of spine biologics.

Geographical Trends: North America currently leads the global market due to its advanced healthcare infrastructure, high healthcare expenditure, and awareness of spinal ailments. Moreover, the Asia-Pacific region is witnessing rapid growth according to the spine biologics market statistics owing to increasing healthcare access, rising economic standards, and a growing geriatric population.

Competitive Landscape: Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet, among many others.

Challenges and Opportunities: The challenges in the market include concerns over the high cost of biologic products and stringent regulatory environments that can delay product launches. As outlined in the spine biologics market overview, the growing collaborations with insurance providers and healthcare facilities hold the potential to improve access to and uptake of biologic treatments generating numerous opportunities.

Spine Biologics Market Trends:

Increasing Prevalence of Spinal Disorders

The growing occurrence of spinal disorders is affecting the spine biologics market growth. In addition, the increasing life expectancy, and lifestyle issues, are spurring the development of degenerative illnesses such as disc disease and spinal stenosis. According to the World Health Organization (WHO) in 2020 approximately 1 in 13 individuals equating to 619 million individuals experienced low back pain (LBP), a 60% increase from 1990. It is further estimated that low back pain cases will increase by around 843 million by 2050 which emphasizes the widespread nature of spinal issues. The rising number of incidences is with the age group of 80 years, and the increasing number of LBP cases occur at the age of 50-55 years. This widespread prevalence necessitates ongoing development and deployment of effective treatments, including biologics, which help promote bone growth and healing, making them critical in treating these pervasive conditions.

Rising Adoption of Minimally Invasive Surgeries (MIS)

Minimally invasive surgeries (MIS) for spinal conditions are preferred due to their less distressful nature and quicker recovery times compared to traditional open surgeries. The global market for minimally invasive surgery is projected to expand at a compound annual growth rate (CAGR) of roughly 6% during 2024-2032 as per the IMARC GROUP. It reached US$ 52.9 Billion in 2023 and anticipates the market to reach US$ 91.0 Billion by 2032. This growth is declarative of a shift in surgical methods that reduce hospital stays and recovery periods, which is particularly beneficial for spine biologics market value.

Growing Geriatric Population

The growing geriatric population is driving the spine biologics market demand. As individuals age, the risk of developing spinal disorders increases, necessitating more frequent and intensive care. As per the data from the UNITED NATIONS population aged 65 and over is expected to rise from 10% in 2022 to 16% in 2050. It is forecasted that individuals aged 65 years or above globally will double the number of children under age 5 and will be equal to the number of 12-year-old children. It means a rising number of age-associated spinal conditions, escalating the demand for treatments that are effective and minimally invasive. For instance, biologics, which aid in the natural healing processes, are particularly suited to meet these needs, aligning with the growing healthcare requirements of an aging global population.

Spine Biologics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, surgery type, and end user.

Breakup by Product:

Spinal Allografts

Machined Bones Allograft

Demineralized Bone Matrix

Bone Graft Substitutes

Bone Morphogenetic Proteins

Synthetic Bone Grafts

Cell Based Matrix

Bone graft substitutes account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes spinal allografts (machined bones allograft, demineralized bone matrix), bone graft substitutes, (bone morphogenetic proteins, synthetic bone grafts), and cell-based matrix. According to the report, bone graft substitutes represented the largest segment.

Bone graft substitutes offer an alternative to customary bone grafts, stipulating structural support and facilitating bone healing processes in spinal surgeries. These substitutes embrace synthetic materials, allografts, and demineralized bone matrix, and are advocated for their aptitude to endorse bone fusion and curb the need for harvesting bone from the patient's own body, minimizing surgical complications and recovery time. As per the statistics by IMARC GROUP, the global bone graft and substitute market reached US$3.2 Billion in 2023. It is estimated to reach US$ 5.1 Billion by 2032 with a compound annual growth rate (CAGR) of 5.2% during 2024-2032. Moreover, various advancements in biomaterials, regenerative medicine, and bone graft substitutes are witnessing increasing adoption in spinal procedures, thus positively increasing the spine biologic market value.

Breakup by Surgery Type:

Open Spine Surgery

Minimally Invasive Spine Surgery

Minimally invasive spine surgery holds the largest share of the industry

A detailed breakup and analysis of the market based on the surgery type have also been provided in the report. This includes open spine surgery and minimally invasive spine surgery. According to the report, minimally invasive spine surgery accounted for the largest market share.

Minimally invasive spine surgery is primarily attributed to the growing preference for minimally invasive procedures among patients and healthcare providers. Minimally invasive spine surgery offers several advantages over traditional open surgeries, including smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times. As a result, it has gained popularity for treating various spinal conditions, such as degenerative disc disease, herniated discs, spinal stenosis, and vertebral fractures. According to the NATIONAL LIBRARY OF MEDICINE, minimally invasive spine (MIS) surgery has advanced significantly with imaging navigation systems, robotics, and endoscopy. More than 400,000 cases are accomplished in the United States annually with spine fusion being the commonly conducted and established treatment options for spine trauma, tumors, structural deformities, and degenerative disorders.

Breakup by End User:

Hospitals

Ambulatory Care Centers

Spinal Surgery Centers

Orthopedic Clinics

Others

Hospitals represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, ambulatory care centers, spinal surgery centers, orthopedic clinics, and others. According to the report, hospitals represented the largest segment.

Hospitals are major centers for specialized medical care that attract a considerable proportion of patients seeking treatments for several forms of spinal disorders including those that necessitate surgeries. Furthermore, some hospitals have dedicated spine centers or departments where they offer services, making them the preferred centers for comprehensive source care. Besides this, hospitals have strong collaborations with spine biologic manufacturers and suppliers, thereby enhancing the efficiency of the equipment. In June 2022, Xenco Medical broadened its range of devices for ambulatory surgery centers by securing Food and Drug Administration (FDA) clearance and introducing its Multilevel CerviKit for their single use. It comprises a complete suite of implants and single-use instruments for two, three, and four level procedures of the anterior cervical spine.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest spine biologics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for spine biologics.

North America's dominance in the market can be attributed to highly developed healthcare infrastructure, the high rate of innovative medical technologies' adoption, and a large patient pool with spinal disorders. For instance, as per the data from the National Spinal Cord Injury Association, approximately 450,000 individuals reside in the United States with a spinal cord injury (SCI). Annually, an estimated 17,000 new cases of SCI arise in the U.S., predominantly stemming from trauma to the vertebral column. Thus, the increasing incidence of SCI population is significantly escalating the demand for spine biologics to treat disorders across the region. Additionally, favorable reimbursement policies, strong R&D efforts, and awareness of the advantages of minimally invasive surgical procedures are generating the spine biologics market revenue in North America.

Competitive Landscape:

The spine biologics market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

At present, key players in the market are investing in research and innovation to develop models that outperform rivals and offer solutions sought by customers. They also work hard to ensure their products remain in the market and meet customers' demands through the development of strategic alliances, acquisitions, and expansions into new markets to penetrate more markets and meet all customer needs. For instance, in October 2023, Orthofix Medical Inc., a prominent global spine and orthopedics corporation unveiled the full commercial release of OsteoCove, which is an innovative bioactive synthetic graft, following its 510k clearance. It is offered in putty and strip forms, meticulously developed to offer exceptional bone-forming capabilities and optimal handling properties for various spine and orthopedic procedures. Moreover, excellent marketing and brand management also make their products highly demanded, which is providing a positive spine biologics market outlook.

Spine Biologics Market News:

August 2022: Graftys SA announced the renewal of its lengthy contract with Arthrex for a multi-year supply agreement concerning advanced synthetic bone graft materials.

October 2023: Stryker, a prominent medical technology company unveiled their Q guidance system with spine guidance software which was deployed to supply improved surgical planning and navigation in over 2,400 spinal cases.

Key Questions Answered in This Report

  • 1. How big is the global spine biologics market?
  • 2. What is the expected growth rate of the global spine biologics market during 2024-2032?
  • 3. What are the key factors driving the global spine biologics market?
  • 4. What has been the impact of COVID-19 on the global spine biologics market?
  • 5. What is the breakup of the global spine biologics market based on the product?
  • 6. What is the breakup of the global spine biologics market based on the surgery type?
  • 7. What is the breakup of the global spine biologics market based on the end user?
  • 8. What are the key regions in the global spine biologics market?
  • 9. Who are the key players/companies in the global spine biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Spine Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Spinal Allografts
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Machined Bones Allograft
      • 6.1.2.2 Demineralized Bone Matrix
    • 6.1.3 Market Forecast
  • 6.2 Bone Graft Substitutes
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Bone Morphogenetic Proteins
      • 6.2.2.2 Synthetic Bone Grafts
    • 6.2.3 Market Forecast
  • 6.3 Cell Based Matrix
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Surgery Type

  • 7.1 Open Spine Surgery
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Minimally Invasive Spine Surgery
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Care Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Spinal Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Orthopedic Clinics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Arthrex Inc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Alphatec Holdings Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Exactech Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Johnson & Johnson
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Medtronic plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 NuVasive Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Orthofix Medical Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Stryker Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Wright Medical Group N.V.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Zimmer Biomet
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Spine Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Spine Biologics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Spine Biologics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Spine Biologics Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Spine Biologics Market: Breakup by Surgery Type (in %), 2023
  • Figure 6: Global: Spine Biologics Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Spine Biologics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Spine Biologics (Spinal Allografts) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Spine Biologics (Spinal Allografts) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Spine Biologics (Bone Graft Substitutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Spine Biologics (Bone Graft Substitutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Spine Biologics (Cell Based Matrix) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Spine Biologics (Cell Based Matrix) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Spine Biologics (Open Spine Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Spine Biologics (Open Spine Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Spine Biologics (Minimally Invasive Spine Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Spine Biologics (Minimally Invasive Spine Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Spine Biologics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Spine Biologics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Spine Biologics (Ambulatory Care Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Spine Biologics (Ambulatory Care Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Spine Biologics (Spinal Surgery Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Spine Biologics (Spinal Surgery Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Spine Biologics (Orthopedic Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Spine Biologics (Orthopedic Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Spine Biologics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Spine Biologics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Spine Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Spine Biologics Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Spine Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Spine Biologics Industry: SWOT Analysis
  • Figure 78: Global: Spine Biologics Industry: Value Chain Analysis
  • Figure 79: Global: Spine Biologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Spine Biologics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Spine Biologics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Spine Biologics Market Forecast: Breakup by Surgery Type (in Million US$), 2024-2032
  • Table 4: Global: Spine Biologics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Spine Biologics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Spine Biologics Market: Competitive Structure
  • Table 7: Global: Spine Biologics Market: Key Players